Literature DB >> 26002977

Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia.

Beth A Lubeck1, Philip E Lapinski1, Jennifer A Oliver1, Olga Ksionda2, Luis F Parada3, Yuan Zhu4, Ivan Maillard5, Mark Chiang5, Jeroen Roose2, Philip D King6.   

Abstract

Ras GTPase-activating proteins (RasGAPs) inhibit signal transduction initiated through the Ras small GTP-binding protein. However, which members of the RasGAP family act as negative regulators of T cell responses is not completely understood. In this study, we investigated potential roles for the RasGAPs RASA1 and neurofibromin 1 (NF1) in T cells through the generation and analysis of T cell-specific RASA1 and NF1 double-deficient mice. In contrast to mice lacking either RasGAP alone in T cells, double-deficient mice developed T cell acute lymphoblastic leukemia/lymphoma, which originated at an early point in T cell development and was dependent on activating mutations in the Notch1 gene. These findings highlight RASA1 and NF1 as cotumor suppressors in the T cell lineage.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26002977      PMCID: PMC4475412          DOI: 10.4049/jimmunol.1402639

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma.

Authors:  S C Cleverley; P S Costello; S W Henning; D A Cantrell
Journal:  Oncogene       Date:  2000-01-06       Impact factor: 9.867

Review 2.  GEFs and GAPs: critical elements in the control of small G proteins.

Authors:  Johannes L Bos; Holger Rehmann; Alfred Wittinghofer
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

3.  Activating Notch1 mutations in mouse models of T-ALL.

Authors:  Jennifer O'Neil; Jennifer Calvo; Keith McKenna; Veena Krishnamoorthy; Jon C Aster; Craig H Bassing; Frederick W Alt; Michelle Kelliher; A Thomas Look
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

4.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

5.  Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.

Authors:  Mark Y Chiang; Lanwei Xu; Olga Shestova; Gavin Histen; Sarah L'heureux; Candice Romany; M Eden Childs; Phyllis A Gimotty; Jon C Aster; Warren S Pear
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 6.  Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis.

Authors:  Philip D King; Beth A Lubeck; Philip E Lapinski
Journal:  Sci Signal       Date:  2013-02-26       Impact factor: 8.192

Review 7.  RAG: a recombinase diversified.

Authors:  Adam G W Matthews; Marjorie A Oettinger
Journal:  Nat Immunol       Date:  2009-07-21       Impact factor: 25.606

Review 8.  Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells.

Authors:  Robert L Kortum; Alexandre K Rouquette-Jazdanian; Lawrence E Samelson
Journal:  Trends Immunol       Date:  2013-03-15       Impact factor: 16.687

9.  T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination.

Authors:  T Hennet; F K Hagen; L A Tabak; J D Marth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Authors:  Doan T Le; Namie Kong; Yuan Zhu; Jennifer O Lauchle; Abigail Aiyigari; Benjamin S Braun; Endi Wang; Scott C Kogan; Michelle M Le Beau; Luis Parada; Kevin M Shannon
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  12 in total

1.  Regulation of the Small GTPase Ras and Its Relevance to Human Disease.

Authors:  Kayla R Kulhanek; Jeroen P Roose; Ignacio Rubio
Journal:  Methods Mol Biol       Date:  2021

2.  RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

Authors:  Takuo Hayashi; Patrice Desmeules; Roger S Smith; Alexander Drilon; Romel Somwar; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2017-11-10       Impact factor: 12.531

3.  Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle.

Authors:  Marsilius Mues; Jeroen P Roose
Journal:  Small GTPases       Date:  2016-05-09

Review 4.  RASopathy Gene Mutations in Melanoma.

Authors:  Ruth Halaban; Michael Krauthammer
Journal:  J Invest Dermatol       Date:  2016-05-25       Impact factor: 8.551

5.  RASAL3 preferentially stimulates GTP hydrolysis of the Rho family small GTPase Rac2.

Authors:  Yoonjae Shin; Yong Woo Kim; Hyemin Kim; Nakyoung Shin; Tae Sung Kim; Taeg Kyu Kwon; Jang Hyun Choi; Jong-Soo Chang
Journal:  Biomed Rep       Date:  2018-07-02

6.  CTNND1 755 T>G Promoter Polymorphism and Risk of Pancreatic Carcinoma in Chinese.

Authors:  Wei Wang; Yang Fei; Sheng-Li Liu
Journal:  J Clin Lab Anal       Date:  2016-08-27       Impact factor: 2.352

7.  RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines.

Authors:  O Ksionda; A A Melton; J Bache; M Tenhagen; J Bakker; R Harvey; S S Winter; I Rubio; J P Roose
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

8.  Co-expression and significance of Dok2 and Ras p21 protein activator 1 in breast cancer.

Authors:  Jiangrong Huang; Xiaochun Peng; Kun Zhang; Chunyan Li; Bo Su; Yanxiang Zhang; Wangui Yu
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

Review 9.  Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.

Authors:  Deborah Bongiovanni; Valentina Saccomani; Erich Piovan
Journal:  Int J Mol Sci       Date:  2017-09-05       Impact factor: 5.923

Review 10.  Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.

Authors:  Camilla Evangelisti; Francesca Chiarini; James A McCubrey; Alberto M Martelli
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.